TrialBlood neoplasia2025

A phase 2 study of decitabine with or without carboplatin and arsenic trioxide in patients with MDS and AML.

Patricia L Kropf et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.